Meeting
2015 Gastrointestinal Cancers Symposium
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
Authors
Li-Tzong Chen
National Institute of Cancer Research, National Health Research Institutes, Tainan City, Taiwan
Li-Tzong Chen , Daniel D. Von Hoff , Chung-Pin Li , Andrea Wang-Gillam , Gyorgy Bodoky , Andrew Peter Dean , Yan-Shen Shan , Gayle S. Jameson , Teresa Macarulla , Kyung-Hun Lee , David Cunningham , Jean-Frédéric Blanc , Richard Hubner , Chang-Fang Chiu , Gilberto Schwartsmann , Jens T Siveke , Fadi S. Braiteh , Victor M. Moyo , Bruce Belanger , Eliel Bayever
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01494506
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 234)
DOI
10.1200/jco.2015.33.3_suppl.234
Abstract #
234
Poster Bd #
A5
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.
First Author: Andrea Wang-Gillam
Poster
2016 Gastrointestinal Cancers Symposium
Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1 trial: A phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
First Author: Li-Tzong Chen
Poster
2016 Gastrointestinal Cancers Symposium
Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
First Author: Andrea Wang-Gillam
Poster
2020 ASCO Virtual Scientific Program
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
First Author: Shintaro Nakano